Authors
Raj Chovatiya, Marjolein de Bruin-Weller, Andrew Alexis, Chesahna Kindred, Mona Shahriari, Jill Waibel, Christian Vestergaard, Natalie Nunez Gomez, Khai Jing Ng, Lucia Seminario-Vidal, Zach Dawson, Chao Yang, Yuxin Ding, Julien Seneschal
Published in
The Journal of dermatological treatment. Volume 37. Issue 1. Pages 2713286. Epub Oct 19, 2026.
Abstract
Head, neck, and face (HNF) atopic dermatitis (AD) substantially impairs quality of life, yet long-term biologic efficacy data in HNF areas remain limited.
This post hoc analysis evaluates HNF efficacy of lebrikizumab across phase 3 trials (ADvocate 1&2, ADjoin) and targeted populations (ADmirable, ADapt) in adolescents (≥12 years, ≥40 kg) and adults with moderate-to-severe AD. Outcomes included HN EASI sub-scores and Face Investigator's Global Assessment (F-IGA).
Lebrikizumab 250 mg Q4W provided durable efficacy through 3 years among week 16 responders. At week 152, 94.8%, 82.9%, and 85.3% maintained HN EASI 75, 90, and 100 responses, respectively.Stable response (maintaining ≥80% of attended visits) through week 152 was observed in 88.8% (HN EASI 75), 80.0% (HN EASI 90), and 74.0% (HN EASI 100) of patients. Additionally, 93.8% achieved absolute HN EASI ≤1 and 69.2% achieved HN EASI = 0 at week 152 in week 16 responders. In ADmirable (skin of color), 61% of Lebri-treated patients achieved F-IGA 0 at week 24. In ADapt (prior dupilumab exposure), 55% achieved F-IGA 0 at week 24.
Lebrikizumab provided durable, stable long-term HNF efficacy across diverse populations, including systemic-naive patients and those with prior biologic exposure.
PMID:
42895209
Bibliographic data and abstract were imported from PubMed on 19 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 29
- Comments 0